APOE2 Attenuates APOE4-Associated Amyloid Changes in an Alzheimer’s Mouse Model
Published in Biology, Brain/Neurology, Journals.
October 8, 2026
A study published today in Nature Communications examines how the APOE2 and APOE4 gene variants interact in a mouse model of Alzheimer’s disease. Researchers compared mice carrying different pairs of human APOE alleles, crossed with the amyloid-producing 5xFAD model.
Mice carrying APOE3/4 showed increased amyloid-beta deposition, altered microglial activation and reduced microglial interactions with plaques. These changes were attenuated in APOE2/4 mice. Their brain protein profiles also resembled those of APOE3/3 and APOE2/3 mice more closely.
The protective pattern was incomplete: increased myelin basic protein was observed in APOE2/3 mice but not APOE2/4 mice, while some plasma lipid changes were shared by APOE3/4 and APOE2/4 animals. The findings suggest that APOE allele combinations affect brain and systemic biology differently.
This is a mechanistic animal study, not a clinical trial or a test of an APOE2 treatment in patients. It helps explain genotype-dependent biology but does not demonstrate prevention or reversal of human Alzheimer’s disease.
Source: Chen and colleagues, Nature Communications, published October 8, 2026. DOI: 10.1038/s41467-026-78407-x.